Novo launched a superior dose of Wegovy (HD) with better efficacy, at a competitive price point, and expanded access via telehealth partnerships. This strengthens Novo's competitive moat against Eli Lilly and could drive market share growth and revenue upside, potentially not yet reflected in the stock price ahead of critical May 5th earnings. Positive product cycle news and strategic moves create a near-term catalyst for the stock, supporting the author's view of potential undervaluation. Earnings miss on May 5th; stronger-than-expected competitive response from Eli Lilly (LLY); regulatory pushback on pricing or distribution.
NVO
HIGH
Apr 09, 07:32
Key Points
['Wegovy HD launch: 3x dose', 'Priced below Zepbound ($399 vs $449)', 'Telehealth partnerships expand access', 'May 5th earnings as catalyst', 'Aims to restrict compounded competitors']
April 09, 2026 at 07:32